OROX BioSciences develops innovative small‑molecule drugs that inhibit soluble epoxide hydrolase (sEH) to modulate lipid metabolism for treating cancer and fibrotic diseases. Leveraging expertise in lipid‑metabolism pathways, the company advances a pipeline of sEH‑based therapeutics aimed at improving efficacy and outcomes in oncology and fibrosis indications.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for many cancers and fibrotic diseases have limited efficacy and can cause significant side effects, leaving substantial unmet medical needs. Dysregulated lipid metabolism contributes to disease progression, but therapeutic strategies that specifically target these pathways are lacking.
Solution
OROX BioSciences develops small‑molecule inhibitors of soluble epoxide hydrolase (sEH) to modulate lipid signaling pathways implicated in oncology and fibrosis. By combining sEH inhibition with secondary pharmacologic targets, the company seeks to enhance anti‑tumor activity and reduce fibrotic tissue formation. Their discovery platform emphasizes rapid identification and optimization of drug‑like molecules, accelerating preclinical development. The approach aims to deliver novel therapeutics that improve disease control while minimizing toxicity compared with existing options.
Target Audience
Primary customers are pharmaceutical companies and research organizations developing oncology and anti‑fibrotic therapies, as well as clinical development partners seeking novel small‑molecule candidates.
Features
- Small‑molecule sEH inhibitors designed to restore beneficial epoxylipid levels
- Dual‑target strategies that pair sEH inhibition with complementary mechanisms of action
- Structure‑based drug design and ADME optimization pipelines for fast lead generation
- Preclinical programs focused on multiple cancer indications and diverse fibrotic disorders
- Proprietary assays to evaluate lipid‑mediated signaling and functional outcomes in disease models